Foghorn therapeutics to participate at the h.c. wainwright bioconnect conference

Cambridge, mass., jan. 07, 2022 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that foghorn will present at the h.c. wainwright bioconnect conference which is being held virtually on january 10th through the 13th, 2022. with an initial focus in oncology, foghorn's gene traffic control platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.
FHTX Ratings Summary
FHTX Quant Ranking